A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

IRB/UVA Tracking #
21781
Contact
Megan Healy
Contact Phone
Phase
II
Primary purpose
Treatment
Cancer PI
Leonid Volodin
Status
OPEN TO ACCRUAL
Ages
Adult